6 days Ago By Defense World Staff
Renaissance Technologies LLC lifted its holdings in shares of Assembly Biosciences, Inc. ( NASDAQ:ASMB – Free Report ) by 44.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission.
The institutional investor owned 94,711 shares of the biopharmaceutical company’s stock after buying an additional 29,087 shares during the quarter. Renaissance Technologies LLC owned about 1.49% of Assembly Biosciences worth $1,495,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently bought and sold shares of the business. JPMorgan Chase & Co. lifted its position in shares of Assembly Biosciences by 5,137.
3% during the third quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 3,442 shares in the last quarter.
Palumbo Wealth Management LLC bought a new position in Assembly Biosciences in the 4th quarter worth about $180,000. Monimus Capital Management LP purchased a new position in Assembly Biosciences during the 4th quarter valued at about $664,000. Finally, Peapod Lane Capital LLC bought a new stake in shares of Assembly Biosciences during the fourth quarter valued at about $994,000.
19.92% of the stock is owned by institutional investors. Wall Street Analysts Forecast Growth A number of research analysts have recently commented on ASMB shares.
Guggenheim assumed coverage on shares of Assembly Biosciences in a research report on Tuesday, March 25th. They set a “buy” rating and a $31.00 price target for the company.
StockNews.com lowered Assembly Biosciences from a “buy” rating to a “hold” rating in a research note on Monday, March 24th. Finally, HC Wainwright reiterated a “neutral” rating on shares of Assembly Biosciences in a research report on Monday, March 24th.
Assembly Biosciences Stock Performance NASDAQ ASMB opened at $10.82 on Tuesday. The company has a market capitalization of $82.
64 million, a P/E ratio of -1.61 and a beta of 0.65.
Assembly Biosciences, Inc. has a 52-week low of $7.75 and a 52-week high of $19.
93. The company has a fifty day moving average of $10.61 and a 200-day moving average of $13.
83. Assembly Biosciences ( NASDAQ:ASMB – Get Free Report ) last posted its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($1.
57) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.75) by $0.18.
Assembly Biosciences had a negative return on equity of 121.46% and a negative net margin of 144.05%.
The firm had revenue of $7.36 million during the quarter, compared to analysts’ expectations of $7.05 million.
As a group, analysts forecast that Assembly Biosciences, Inc. will post -6.87 EPS for the current fiscal year.
Assembly Biosciences Profile ( Free Report ) Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. See Also Five stocks we like better than Assembly Biosciences 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion Best Defense Stocks in 2025.
.. So Far What Are Some of the Best Large-Cap Stocks to Buy? Alphabet Rebounds After Strong Earnings and Buyback Announcement Compound Interest and Why It Matters When Investing Could Selling Taiwan Semiconductor Be Buffett’s Biggest Regret? Want to see what other hedge funds are holding ASMB? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Assembly Biosciences, Inc. ( NASDAQ:ASMB – Free Report ). Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.
com's FREE daily email newsletter ..
